Trial Profile
A phase II trial of NSI 566 in patients with amyotrophic lateral sclerosis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs NSI 566 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 19 Mar 2015 New trial record